1. Introduction {#s0005}
===============

Glycosylphosphatidylinositol (GPI) acts as a membrane anchor for a small but significant proportion of higher eukaryote cell-surface glycoproteins that are particularly abundant in protozoan parasites such as *Trypanosoma brucei*, the causative agent of African sleeping sickness in humans and the related disease Nagana in cattle.[@b0005] The structure, biosynthesis, and function of GPI anchors and related molecules have been extensively reviewed.[@b0005; @b0140; @b0145; @b0150] Disruption of GPI biosynthesis in the clinically relevant bloodstream form of *T. brucei* has been genetically[@b0025; @b0030; @b0035; @b0155] and chemically[@b0045] validated as a drug target.

A key early step in the biosynthesis of the GPI anchors is the de-*N*-acetylation of 2-acetamido-2-deoxy-α-[d]{.smallcaps}-glucopyranosyl-(1→6)-phosphatidylinositol[@b0050] \[α-[d]{.smallcaps}-Glc*p*NAc-PI (**1**, [Fig. 1](#f0005){ref-type="fig"})\] to form α-[d]{.smallcaps}-Glc*p*NH~2~-PI (**2**, [Fig. 1](#f0005){ref-type="fig"}). De-*N*-acetylation is a prerequisite for subsequent processing of **2** that leads to mature GPI anchor precursors.[@b0055] In *T. brucei*, de-*N*-acetylation is followed by mannosylation and subsequent inositol-acylation of **2,** whereas in mammalian cells the order of these reactions is reversed.[@b0060; @b0065]

Previously, we have shown[@b0070] that mammalian and trypanosomal α-[d]{.smallcaps}-Glc*p*NAc-PI de-*N*-acetylases are zinc metalloenzymes, proposed a mechanism of action similar to that of zinc peptidases and postulated that known zinc binding motifs[@b0075; @b0080] such as the *N*-hydroxyurea analogue **3** ([Fig. 1](#f0005){ref-type="fig"}),[@b0085] could act as inhibitors. Here, we have designed and synthesised a small library of deoxymonosaccharides \[**5**--**12** ([Fig. 2](#f0010){ref-type="fig"})\] containing recognisable zinc binding groups (ZBGs), that is, carboxylic acids and hydroxamic acids, as well as a potentially new ZBG, the ureido derivative, that should continue to probe the trypanosomal α-[d]{.smallcaps}-Glc*p*NAc-PI de-*N*-acetylase.

A good starting point for our compound library was the earlier work by Hindsgaul and co-workers[@b0090; @b0095] which demonstrated the effectiveness of 1,5-anhydro-2-deoxy-[d]{.smallcaps}-glucitol hydroxamic acids, for example **7**,[@b0095] as ZBG probes. The hydroxamic acid **7** was resynthesised and included in the compound library because **7** was shown to be a potent inhibitor of LpxC,[@b0095] presumably via zinc chelation, and could serve as the standard by which to compare the potency of the other analogues in the library. Therefore, compounds **5**, **6** and **8**[†](#fn1){ref-type="fn"} resemble those of Hindsgaul et al. whereby the 2-C appendage is either a hydroxamic acid or a carboxylic acid ZBG moiety. Compounds **9**--**11** were synthesised to supply potential glycosyl donors for another project but might also exhibit some degree of inhibition towards the trypanosome de-*N*-acetylase enzyme. Lastly, the *N*-ureido thioglycoside **12** was fashioned because of previous inhibitory data of the *N*-ureido-GlcNAc-PI derivative **4**[@b0100] ([Fig. 1](#f0005){ref-type="fig"}) against the trypanosome de-*N*-acetylase enzyme. Analogue **12** is a truncated version of **4** which focuses on, what we believe to be the most potent inhibitory component of **4**, the *N*-ureido motif.

2. Results and discussion {#s0010}
=========================

The synthesis, of the analogues **5**--**8**, is based on a successful approach[@b0090; @b0095] used previously ([Scheme 1](#f0015){ref-type="fig"}).

The first three steps, benzoylation→ozonolysis→Pinnick[@b0105] oxidation, from the known[@b0090] 2-*C*-allyl derivative **13** was accomplished straightforwardly to furnish the pivotal carboxylic acid **14**.[@b0095] The carboxylic acid analogue **14**[@b0095] and the corresponding intermediates from **13**[@b0090] were not fully characterised in the literature. Consequently, we have included the analytical data for those intermediates, and that of compound **14**,[@b0095] in this paper as [Supplementary data](#s0125){ref-type="sec"}. Hydrogenolysis of the benzylidene protecting group of compound **14** furnished the target analogue **5** in 59% yield; alternatively, the yield could be improved to 70% by using aqueous TFA.

The synthesis of carboxylic acid **6** emerged from the de-*O*-benzoylation of **14**,[@b0095] under Zemplén conditions, followed by hydrogenolysis over 10% palladium on carbon to give the crude derivative **6** ([Scheme 1](#f0015){ref-type="fig"}). The analogue **6** was then purified by reversed phase chromatography (RPC) to afford the final target glucitol **6** in 80% yield.

The carboxylic acid derivative **14**[@b0095] was coupled with *O*-benzylhydroxylamine hydrochloride (BnONH~2~·HCl) using *N*-(3-dimethylaminopropyl)-*N*′-ethylcarbodiimide hydrochloride (EDAC) to give the known[@b0095] hydroxyamide **16** (see the [Supplementary data](#s0125){ref-type="sec"} for the analytical data of **16**). The benzyloxyamide **16** was hydrogenated, as described in the literature, to give the hydroxamic acid **7**;[@b0095] ^1^H NMR assignments for **7** were identical to those reported in the literature[@b0095] and see the [Supplementary data](#s0125){ref-type="sec"} for the ^13^C NMR assignments of **7**. The ZBG analogue **8** was synthesised following the sequence **16**→**17**[@b0090]→**8**, as previously described for **6**. An alternative synthesis of the derivative **17**[@b0090] is described in the [Supplementary data](#s0125){ref-type="sec"}.

The synthesis of the targeted carboxylic acid **9** ([Scheme 2](#f0020){ref-type="fig"}) began from the acetolysis of the 1,6-anhydro derivative **18**[@b0110] to give, exclusively, the α-2-*C*-allyl derivative **19** \[*J*~1,2~ = 3.1 Hz\]. The tetraacetate derivative **19** proved to be a very useful intermediate because **19** could be altered to supply analogues **10** and **11**, as well. Thus, a portion of the 2-*C*-allyl intermediate **19** was ozonised to give the aldehyde **20**, which was oxidised, following Pinnicks' protocols,[@b0105] to furnish the carboxylic acid **21** in 94% yield. Lastly, the tetraacetate **21** was de-*O*-acetylated with 0.03 M methanolic sodium methoxide to produce the fully deprotected carboxylic acid analogue **9** in 51% yield, as a mixture of α/β anomers.

Another portion of the 2-*C*-allyl derivative **19** was transformed into the corresponding α- and β-phenylthioglucosides **22** and **23**, respectively, via Lewis acid (BF~3~·Et~2~O) catalysed substitution of the anomeric acetate with thiophenol in refluxing dichloromethane.[@b0115] These two anomers were separated by radial band chromatography to furnish the α-anomer **22** (*J*~1,2~ = 4.9 Hz) and the β-anomer **23** (*J*~1,2~ = 10.9 Hz) in 48% and 13% yields, respectively. The closing sequences **22**→**24**→**26**→**10** and **23**→**25**→**27**→**11** were then conducted without incident, essentially as those described for **9**; the exception being **26**→**10** which was achieved via acid hydrolysis[@b0120] ([Scheme 2](#f0020){ref-type="fig"}).

A synthesis of 1-thiophenyl-2-deoxy-2-ureido-β-[d]{.smallcaps}-glucopyranoside **12** was obtained on treatment of the known amine[@b0125] **28** with potassium cyanate (KOCN) and water at room temperature in total darkness[@b0130; @b0135] ([Scheme 3](#f0025){ref-type="fig"}). After evaporation to dryness, the crude ureido compound was purified by reversed phase chromatography to give crystalline **12** (65% yield; characteristic ^13^C carbonyl carbon at *δ* 158.47 ppm).

Details of the results of enzymatic studies with the above ZBG analogues will be reported elsewhere in due course.

3. Experimental {#s0015}
===============

3.1. General methods {#s0020}
--------------------

^1^H, ^13^C, ^31^P NMR spectra were recorded on a Bruker AVANCE 500 MHz spectrometer using deuteriochloroform as a solvent and tetramethylsilane as the internal standard, unless otherwise indicated. All coupling constants (*J*) are given in Hertz. High resolution electrospray ionisation mass spectra (HRESIMS) and liquid chromatography mass spectra (LCMS) were recorded with a Bruker microTof spectrometer. Melting points were determined on a Reichert hot-plate apparatus and are uncorrected. Optical rotations were measured with a Perkin--Elmer 343 polarimeter. Thin layer chromatography (TLC) was performed on Kieselgel 60 F~254~ (Merck) or RP-18 F~254s~ (Merck) plates with various solvent systems as developers, followed by detection under UV light or by charring using either sulfuric acid--water--ethanol (15:85:5), phosphomolybdic acid, orcinol or ninhydrin spray reagents. Flash column chromatography (FCC) was performed on Kieselgel 60 (0.040--0.063 mm) (Merck). Reversed phase chromatography was performed on a C18 cartridge supplied by Sigma--Aldrich. Radial-band chromatography (RBC) was performed using a Chromatotron (model 7924T, TC Research UK) with silica gel F~254~ TLC standard grade as the adsorbent. All reactions were carried out in commercially available dry solvents, unless otherwise stated. Light petroleum refers to the fraction having a boiling range 60--80 °C, unless indicated otherwise.

3.2. Synthesis of the ZBG library {#s0025}
---------------------------------

### 3.2.1. 1,5-Anhydro-3-*O*-benzoyl-2-*C-*carboxymethyl-2-deoxy-[d]{.smallcaps}-glucitol (**5**) {#s0030}

#### 3.2.1.1. Method A {#s0035}

A solution of the benzylidene compound **14**[@b0095] (20 mg, 0.05 mmol) in AcOH (2 mL) containing 10% palladium on carbon (10 mg) was stirred under a slight overpressure of hydrogen at room temperature for 4 h. The reaction mixture was filtered through a pad of Celite and concentrated under reduced pressure. The residue was purified by FCC (10:1:0.02 CHCl~3~--MeOH--AcOH) to furnish a brown paste **5** (9 mg, 59%), which was indistinguishable from that obtained by the following procedure.

#### 3.2.1.2. Method B {#s0040}

A solution of the benzylidene compound **14**[@b0095] (40 mg, 0.10 mmol) in THF (2 mL) and 96% (aq) TFA (0.5 mL) was stirred at room temperature for 3 h. The reaction mixture was concentrated under reduced pressure and co-evaporated with toluene (2 × 5 mL). The residue was purified with the same solvent system as in method A to give the acid **5** (21 mg, 70%): *R*~f~ 0.20 (10:1:0.02 CHCl~3~--MeOH--AcOH); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +8.9 (*c* 1.0, MeOH); ^1^H NMR (CD~3~OD**,** 500 MHz): *δ* 8.10--7.49 (m, 5H, Ph), 5.10 (dd, 1H, *J*~2,3~ 10.7, *J*~3,4~ 9.3 Hz, H-3), 4.10 (dd, 1H, *J*~1a,2~ 4.7, *J*~1a,1b~ 11.5 Hz, H-1a), 3.88 (dd, 1H, *J*~5,6a~ 2.1, *J*~6a,6b~ 11.8 Hz, H-6a), 3.71 (dd, 1H, H-6b), 3.60 (t, 1H, *J*~4,5~ 9.3 Hz, H-4), 3.40 (t, 1H, *J*~1a,1b~ 11.5 Hz, H-1b), 3.37--3.34 (m, 1H, H-5), 2.50--2.41 (m, 1H, H-2), 2.35 (dd, 1H, *J*~2,7a~ 4.8, *J*~7a,7b~ 16.0 Hz, H-7a), 2.17 (dd, 1H, H-7b); ^13^C NMR (CD~3~OD, 125 MHz): *δ* 175.49 (C000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000O), 168.15 (Ph*C*O), 134.29--129.56 (C-Ph), 82.75 (C-5), 79.92 (C-3), 70.79 (C-4), 70.56 (C-1), 62.94 (C-6), 40.03 (C-2), 34.10 (C-7). HRESIMS: Calcd for \[C~15~H~18~O~7~−H\]^−^: 309.0980. Found *m/z*: 309.0967.

### 3.2.2. 1,5-Anhydro-4,6-*O*-benzylidene-2-*C-*carboxymethyl-2-deoxy-[d]{.smallcaps}-glucitol (**15**) {#s0045}

A methanolic 0.03 M MaOMe (0.6 mL, 0.018 mmol) solution was added to the benzoate derivative **14**[@b0095] (60 mg, 0.15 mmol) in THF--MeOH (1:4 5 mL) and the reaction mixture was stirred overnight at room temperature. Afterwards, the reaction mixture was neutralised with Amberlite IR-120 (H^+^) ion-exchange resin, filtered and the filtrate concentrated under reduced pressure and co-evaporated with water (5 × 5 mL). The residue was purified by FCC (20:1:0.02 CH~2~Cl~2~--MeOH--AcOH) to give the crystalline acid **15** (33 mg, 75%): mp 183--185 °C; *R*~f~ 0.24 (20:1:0.02 CH~2~Cl~2~--MeOH--AcOH); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ −209.0 (*c* 1.0, MeOH); ^1^H NMR (CD~3~OD, 500 MHz): *δ* 7.50--7.33 (m, 5H, Ph), 5.58 (s, 1H, PhC*H*), 4.20 (dd, 1H, *J*~5,6a~ 5.0, *J*~6a,6b~ 10.3 Hz, H-6a), 4.02 (dd, 1H, *J*~1a,2~ 4.7, *J*~1a,1b~ 11.4 Hz, H-1a), 3.70 (t, 1H, *J*~6a,6b~ 10.3 Hz, H-6b), 3.50--3.45 (m, 2H, H-3, H-4), 3.37--3.28 (m, 2H, H-1b, H-5), 2.77 (dd, 1H, *J*~2,7a~ 3.0, *J*~7a,7b~ 15.8 Hz, H-7a), 2.21--2.14 (m, 1H, H-2), 2.11 (dd, 1H, H-7b); ^13^C NMR (CD~3~OD, 125 MHz): *δ* 176.06 (CO), 139.32--127.56 (C-Ph), 103.06 (Ph*C*H), 84.55 (C-4), 73.57 (C-3), 73.17 (C-5), 71.46 (C-1), 69.84 (C-6), 41.88 (C-2), 33.58 (C-7). HRESIMS: Calcd for \[C~15~H~18~O~6~−H\]^−^: 293.1031. Found *m/z*: 293.1030.

### 3.2.3. 1,5-Anhydro-2-*C-*carboxymethyl-2-deoxy-[d]{.smallcaps}-glucitol (**6**) {#s0050}

A solution of the benzylidene derivative **15** (58 mg, 0.20 mmol) in AcOH (10 mL) containing 10% palladium on carbon (29 mg) was stirred under a slight overpressure of hydrogen at room temperature for 3 h. The reaction mixture was filtered through a pad of Celite and concentrated under reduced pressure. The resulting residue was purified by an RPC C18 column (10% MeOH) to furnish the carboxylic acid **6** (32 mg, 80%): *R*~f~ 0.40 (10% MeOH); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +379.6 (*c* 0.5, MeOH); ^1^H NMR (CD~3~OD, 500 MHz): *δ* 3.99 (dd, 1H, *J*~1a,2~ 3.9, *J*~1a,1b~ 11.5 Hz, H-1a), 3.83 (dd, 1H, *J*~5,6a~ 2.1, *J*~6a,6b~ 11.8 Hz, H-6a), 3.62 (dd, 1H, H-6b), 3.23 (t, 1H, *J*~3,4~ = *J*~4,5~ = 8.6 Hz, H-4), 3.19--3.15 (m, 3H, H-1b, H-3, H-5), 2.77--2.71 (m, 1H, H-7a), 2.08--2.00 (m, 2H, H-2, H-7b); ^13^C NMR (CD~3~OD, 125 MHz): *δ* 176.44 (CO), 82.71 (C-5), 77.59 (C-3), 73.12 (C-4), 70.81 (C-1), 63.26 (C-6), 41.34 (C-2), 33.83 (C-7). HRESIMS: Calcd for \[C~8~H~14~O~6~−H\]^−^: 205.0718. Found *m/z*: 205.0724.

### 3.2.4. 1,5-Anhydro-2-*C-*(carboxymethyl *N*-hydroxyamide)-2-deoxy-[d]{.smallcaps}-glucitol (**8**) {#s0055}

10% Palladium on carbon (40 mg) was added to a solution of the benzyloxyamide **17**[@b0090] (40 mg, 0.10 mmol) in AcOH (10 mL). The reaction mixture was stirred under a slight over pressure of hydrogen at room temperature for 4 h. After filtration through a pad of Celite the solvent was concentrated under reduced pressure. The resulting residue was purified by an RPC C18 column (10% MeOH) to furnish the hydroxamic acid **8** (13.6 mg, 62%): *R*~f~ 0.38 (10% MeOH); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +38.9 (*c* 1.3, MeOH); ^1^H NMR (CD~3~OD, 500 MHz): *δ* 3.92 (dd, 1H, *J*~1a,2~ 4.6, *J*~1a,1b~ 11.5 Hz, H-1a), 3.83 (dd, 1H, *J*~5,6a~ 1.9, *J*~6a,6b~ 11.8 Hz, H-6a), 3.61 (dd, 1H, H-6b), 3.24--3.13 (m, 4H, H-1b, H-3, H-4, H-5), 2.54 (dd, 1H, *J*~2,7a~ 3.9, *J*~7a,7b~ 14.3 Hz, H-7a), 2.06--1.95 (m, 1H, H-2), 1.84 (dd, 1H, H-7b); ^13^C NMR (CD~3~OD, 125 MHz): *δ* 171.44 (CO), 82.72, 77.99, 73.08, 70.66 (C-1), 63.26 (C-6), 41.64 (C-2), 32.66 (C-7). HRESIMS: Calcd for \[C~8~H~15~NO~6~+Na\]^+^: 244.0792. Found *m/z*: 244.0795.

### 3.2.5. 1,3,4,6-Tetra-*O*-acetyl-2-*C*-allyl-2-deoxy-α-[d]{.smallcaps}-glucopyranose (**19**) {#s0060}

A solution of the known[@b0110] 1,6-anhydro derivative **18** (0.865 g, 3.2 mmol) in Ac~2~O--trifluoroacetic acid (9:1, 20 mL) was stirred at room temperature overnight, whereafter it was neutralised with a solution of satd NaHCO~3~. The aqueous solution was extracted with CH~2~Cl~2~ (2 × 200 mL) and the organic extracts were combined, washed with H~2~O (200 mL), brine (200 mL), dried with MgSO~4~ and then concentrated under reduced pressure. The residue was purified by FCC (5:1→2:1 light petroleum--EtOAc) to give the tetraacetate **19** as white needles (1.17 g, 98%): mp 99--101 °C (from 10:1 light petroleum--EtOH); *R*~f~ 0.20 (1:1 light petroleum--EtOAc); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +123.0 (*c* 1.0, CHCl~3~); ^1^H NMR (CDCl~3~, 500 MHz): *δ* 6.06 (d, 1H, *J*~1,2~ 3.1 Hz, H-1), 5.65--5.57 (m, 1H, H-8), 5.20 (t, 1H, *J*~2,3~ = *J*~3,4~ = 10.8 Hz, H-3), 5.01--4.91 (m, 3H, H-4, H-9a,b), 4.23 (dd, 1H, *J*~5,6a~ 4.0, *J*~6a,6b~ 12.4 Hz, H-6a), 3.97--3.93 (m, 2H, H-5, H-6b), 2.16--2.12 (m, 2H, H-2, H-7a), 2.09, 2.00, 1.97, 1.96 (4 × s, 12H, 4 × CH~3~CO), 1.97--1.93 (m, 1H, H-7b); ^13^C NMR (CDCl~3~, 125 MHz): *δ* 169.78, 169.60, 168.83, 167.96 (4 × CO), 133.06 (C-8), 116.54 (C-9), 90.68 (C-1), 70.81 (C-3), 68.73 (C-5), 68.09 (C-4), 60.90 (C-6), 41.89 (C-2), 30.71 (C-7), 19.82, 19.76, 19.70, 19.53, (4 × *C*H~3~CO). HRESIMS: Calcd for \[C~17~H~24~O~9~+Na\]^+^: 395.1313. Found *m/z*: 395.1298.

### 3.2.6. 1,3,4,6-Tetra-*O*-acetyl-2-deoxy-2-*C*-formylmethyl-α-[d]{.smallcaps}-glucopyranose (**20**) {#s0065}

Ozone was passed through a solution of the allyl compound **19** (150 mg, 0.403 mmol) in CH~2~Cl~2~ (20 mL) at −78 °C until the solution turned blue. The excess ozone was removed by a stream of argon until the solution was clear and then followed by the addition of triphenylphosphine (264.3 mg, 1.01 mmol). The mixture was allowed to warm to room temperature for 2 h, concentrated under reduced pressure and purified by RBC (6:1→2:1 light petroleum--EtOAc) to give the aldehyde **20** (84 mg, 88%): *R*~f~ 0.28 (1:1 light petroleum--EtOAc); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +172.7 (*c* 0.6, CHCl~3~); ^1^H NMR (CDCl~3~, 500 MHz): *δ* 9.61 (t, 1H, *J* 1.2 Hz, HCO), 6.20 (d, 1H, *J*~1,2~ 3.4 Hz, H-1), 5.18 (dd, 1H, *J*~2,3~ 11.4, *J*~3,4~ 9.5 Hz, H-3), 5.03 (t, 1H, *J*~4,5~ 9.5 Hz, H-4), 4.23 (dd, 1H, *J*~5,6a~ 4.6, *J*~6a,6b~ 13.0 Hz, H-6a), 4.01--3.97 (m, 2H, H-5, H-6b), 2.76--2.70 (m, 1H, H-2), 2.38 (m, 2H, H-7a, H-7b), 2.09, 2.02, 19.96, 19.94 (4 × s, 12H, 4 × CH~3~CO); ^13^C NMR (CDCl~3~, 125 MHz): *δ* 197.80 (HCO), 169.70, 169.52, 168.66, 167.88 (4 × CO), 90.86 (C-1), 70.18 (C-3), 68.84 (C-5), 67.80 (C-4), 60.73 (C-6), 41.42 (C-7), 36.92 (C-2), 19.85, 19.80, 19.70, 19.62, (4 × *C*H~3~CO). HRESIMS: Calcd for \[C~16~H~22~O~10~+Na\]^+^: 397.1313. Found *m/z*: 397.1298.

### 3.2.7. 1,3,4,6-Tetra-*O*-acetyl-2-*C*-carboxymethyl-2-deoxy-α-[d]{.smallcaps}-glucopyranose (**21**) {#s0070}

A solution of sodium chlorite (2.58 g, 28.56 mmol) and sodium dihydrogen phosphate (3.92 g, 32.63 mmol) in water (20 mL) was added dropwise to a solution of the aldehyde **20** (724 mg, 1.931 mmol) in *tert*-BuOH (56.7 mL, 604 mmol) and amylene (17 mL, 203 mmol). The reaction mixture was stirred for 1 h then diluted with ice water and extracted with EtOAc (2 × 50 mL). The combined organic extracts were washed with brine (30 mL), dried (Na~2~SO~4~), and concentrated under reduced pressure. The residue was purified by FCC (1:1:0.02 light petroleum--EtOAc--AcOH) to furnish the acid **21** (709 mg, 94%): *R*~f~ 0.27 (1:1:0.02 light petroleum--EtOAc--AcOH); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +88.3 (*c* 1.3, CHCl~3~); ^1^H NMR (CDCl~3~, 500 MHz): *δ* 6.25 (d, 1H, *J*~1,2~ 3.4 Hz, H-1), 5.22 (dd, 1H, *J*~2,3~ 11.4, *J*~3,4~ 9.5 Hz, H-3), 5.03 (t, 1H, *J*~4,5~ 9.5 Hz, H-4), 4.28 (dd, 1H, *J*~5,6a~ 4.1, *J*~6a,6b~ 12.4 Hz, H-6a), 4.08--4.02 (m, 2H, H-5, H-6b), 2.61--2.56 (m, 1H, H-2), 2.34 (dd, 1H, *J*~2,7a~ 5.8, *J*~7a,7b~ 16.3 Hz, H-7a), 2.27 (dd, 1H, H-7b), 2.04, 2.01, 2.00, 19.99 (4 × s, 12H, 4 × CH~3~CO); ^13^C NMR (CDCl~3~, 125 MHz): *δ* 174.59, 172.40, 172.14, 171.44, 170.75 (5 × CO), 93.16 (C-1), 72.67 (C-3), 71.13 (C-5), 70.45 (C-4), 63.16 (C-6), 41.79 (C-2), 32.98 (C-7), 20.79, 20.75, 20.70, 20.65 (4 × *C*H~3~CO). HRESIMS: Calcd for \[C~16~H~22~O~11~−H\]^−^: 389.1089. Found *m/z*: 389.1085.

### 3.2.8. 2-*C*-Carboxymethyl-2-deoxy-[d]{.smallcaps}-glucopyranose (**9**) {#s0075}

To a solution of benzoylated compound **21** (93 mg, 0.238 mmol) in MeOH (2 mL) was added 0.03 M sodium methoxide in MeOH (6.2 mL, 0.186 mmol) at room temperature. After 48 h, the reaction mixture was neutralised with Amberlite IR-120 (H^+^) ion-exchange resin, filtered and the filtrate was concentrated under reduced pressure; followed by co-evaporation with water (5 × 5 mL). The residue was purified by FCC (3:1:0.02 CH~2~Cl~2~--MeOH--AcOH) to give the carboxylic acid **9** as an α:β (1.5:1) mixture (27 mg, 51%): *R*~f~ 0.25 (3:1:0.02 CH~2~Cl~2~--MeOH--AcOH); ^1^H NMR (CD~3~OD, 500 MHz): *δ* 5.23 (d, 1H, *J*~1,2~ 3.1 Hz, H-1α), 4.63 (d, *J*~1,2~ 8.6 Hz, H-1β), 3.85 (dd, *J*~5,6a~ 1.9, *J*~6a,6b~ 11.7 Hz, H-6aβ), 3.80--3.76 (m, 2H, H-5, H-6aα), 3.70 (dd, *J*~6a,6b~ 11.4 Hz, H-6bα), 3.66 (dd, H-6bβ), 3.51 (dd, *J*~2,3~ 10.9, *J*~3,4~ 8.9 Hz, H-3α), 3.36 (dd, *J*~2,3~ 10.7, *J*~3,4~ 8.1 Hz, H-3β), 3.32--3.21 (m, 3H, H-4α, H-4β, H-5β), 2.71 (dd, *J*~2,7a~ 3.3, *J*~7a,7b~ 16.6 Hz, H-7aα), 2.60 (dd, *J*~2,7a~ 4.1, *J*~7a,7b~ 16.1 Hz, H-7aβ), 2.46 (dd, H-7bβ), 2.39 (dd, H-7bα), 2.08--2.03 (m, 1H, H-2α), 1.91--1.85 (m, 1H, H-2β); ^13^C NMR (CD~3~OD, 125 MHz): *δ* 177.02, 175.55 (2 × CO), 98.23 (C-1β), 93.79 (C-1α), 77.99 (C-5β), 76.06 (C-3β), 73.25 (C-5α), 73.17 (C-3α), 72.90 (C-4), 63.06 (C-6β), 63.02 (C-6α) 47.62 (C-2β), 44.83 (C-2α), 33.62 (C-7α), 33.51 (C-7β). HRESIMS: Calcd for \[C~8~H~14~O~7~−H\]^−^: 221.0667. Found *m/z*: 221.0659.

### 3.2.9. Phenyl 3,4,6-tri-*O*-acetyl-2-*C*-allyl-2-deoxy-1-thio-α- and β-[d]{.smallcaps}-glucopyranoside (**22**) and (**23**) {#s0080}

To a stirred solution of the tetraacetate **19** (200 mg, 0.537 mmol) in freshly distilled CH~2~Cl~2~ (10 mL) at room temperature under argon was added thiophenol (110 μL, 1.074 mmol) and boron trifluoride diethyl etherate (270 μL, 2.148 mmol). The resulting mixture was heated to reflux for 3 h, cooled to room temperature, and then diluted with CH~2~Cl~2~ (10 mL), washed with satd NaHCO~3~ (10 mL), brine (10 mL), dried (Na~2~SO~4~), and concentrated under reduced pressure. RBC (10:1→4:1 light petroleum--EtOAc) of the residue provided the α-anomer **22** (95 mg, 48%), the β-anomer **23** (25.7 mg, 13%), as well as, an α/β mixture (51.5 mg, 26%).

α-Anomer **22**: *R*~f~ 0.28 (4:1 light petroleum--EtOAc); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +281.0 (*c* 1.0, CHCl~3~); ^1^H NMR (CDCl~3~, 500 MHz): *δ* 7.47--7.27 (m, 5H, Ph) 5.76--5.68 (m, 1H, H-8), 5.46 (d, 1H, *J*~1,2~ 4.9 Hz, H-1), 5.23--5.18 (m, 2H, H-3, H-9a), 5.08 (dd, 1H, *J* 9.8 Hz, H-9b), 5.00 (t, 1H, *J*~3,4~ = *J*~4,5~ = 10.2 Hz, H-4), 4.63--4.60 (m, 1H, H-5), 4.31 (dd, 1H, *J*~5,6a~ 5.2, *J*~6a,6b~ 12.3 Hz, H-6a), 4.01 (dd, 1H, H-6b), 2.44--2.38 (m, 1H, H-2), 2.32--2.26 (m, 1H, H-7a), 2.25--2.16 (m, 1H, H-7b) 2.05, 2.04, 2.03 (3 × s, 12H, 3 × CH~3~CO); ^13^C NMR (CDCl~3~, 125 MHz): *δ* 170.63, 170.31, 169.97 (3 × CO), 134.06 (C-8), 133.57--127.64 (C-Ph), 117.94 (C-9), 88.09 (C-1), 72.46 (C-3), 69.98 (C-4), 68.80 (C-5), 62.41 (C-6), 45.04 (C-2), 33.03 (C-7), 20.73, 20.72, 20.69 (3 × *C*H~3~CO). HRESIMS: Calcd for \[C~21~H~26~O~7~S+Na\]^+^: 445.1291. Found *m/z*: 445.1294.

β-Anomer **23**: *R*~f~ 0.24 (4:1 light petroleum--EtOAc); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +60.0 (*c* 0.2, CHCl~3~); ^1^H NMR (CDCl~3~, 500 MHz): *δ* 7.56--7.31 (m, 5H, Ph) 5.80--5.71 (m, 1H, H-8), 5.14--5.08 (m, 3H, H-3, H-9a, H-9b), 4.94 (dd, 1H, *J*~3,4~ = *J*~4,5~ = 10.0 Hz, H-4), 4.55 (d, 1H, *J*~1,2~ 10.9 Hz, H-1), 4.24 (dd, 1H, *J*~5,6a~ 5.6, *J*~6a,6b~ 12.1 Hz, H-6a), 4.13 (dd, 1H, H-6b), 3.65--3.60 (m, 1H, H-5), 2.45--2.40 (m, 1H, H-7a), 2.34--2.29 (m, 1H, H-7b), 2.07 (s, 3H, CH~3~CO), 2.06--2.02 (m, 1H, H-2), 2.01, 2.00 (2 × s, 6H, 2 × CH~3~CO); ^13^C NMR (CDCl~3~, 125 MHz): *δ* 170.71, 170.29, 169.94 (3 × CO), 132.47 (C-8), 132.79--128.11 (C-Ph), 118.93 (C-9), 86.45 (C-1), 75.32 (C-5), 73.16 (C-3), 69. 86 (C-4), 62.70 (C-6), 43.81 (C-2), 32.05 (C-7), 20.79, 20.75, 20.70 (3 × *C*H~3~CO).

### 3.2.10. Phenyl 3,4,6-tri-*O*-acetyl-2-deoxy-2-*C*-formylmethyl-1-thio-α-[d]{.smallcaps}-glucopyranoside (**24**) {#s0085}

This compound was prepared from the allyl derivative **22** (95 mg, 0.225 mmol) and then quenched with triphenylphosphine (147 mg, 0.562 mmol) essentially as described for **20**. RBC (6:1→2:1 light petroleum--EtOAc) of the residue yielded the aldehyde **24** (84 mg, 88%): *R*~f~ 0.21 (2:1 light petroleum--EtOAc); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +268.27 (*c* 0.9, CHCl~3~); ^1^H NMR (CDCl~3~, 500 MHz): *δ* 9.74 (s, 1H, HCO), 7.44--7.28 (m, 5H, Ph), 5.75 (d, 1H, *J*~1,2~ 5.1 Hz, H-1), 5.16 (dd, 1H, *J*~2,3~ 11.5, *J*~3,4~ 9.5 Hz, H-3), 5.04 (t, 1H, *J*~4,5~ 9.5 Hz, H-4), 4.61--4.56 (m, 1H, H-5), 4.32 (dd, 1H, *J*~5,6a~ 5.1, *J*~6a,6b~ 12.3 Hz, H-6a), 4.05 (dd, 1H, H-6b), 3.03--2.95 (m, 1H, H-2), 2.76 (dd, 1H, *J*~2,7a~ 8.1, *J*~7a,7b~ 18.3 Hz, H-7a), 2.61 (dd, 1H, H-7b), 2.07, 2.04, 2.02 (3 × s, 9H, 3 × CH~3~CO); ^13^C NMR (CDCl~3~, 125 MHz): *δ* 198.86 (HCO), 170.63, 170.31, 169.85 (3 × CO), 132.96--127.85 (C-Ph), 87.52 (C-1), 71.92 (C-3), 69.54 (C-4), 68.62 (C-5), 62.24 (C-6), 43.37 (C-7), 39.7 3 (C-2), 20.72, 20.69, 20.67 (3 × *C*H~3~CO). HRESIMS: Calcd for \[C~20~H~24~O~8~S+Na\]^+^: 447.1084. Found *m/z*: 447.1096.

### 3.2.11. Phenyl 3,4,6-tri-*O*-acetyl-2-deoxy-2-*C*-formylmethyl-1-thio-β-[d]{.smallcaps}-glucopyranoside (**25**) {#s0090}

This compound was prepared from the allyl derivative **23** (25 mg, 0.059 mmol) essentially as described for the previous α-derivative **24**. However, dimethyl sulfide (130 μL, 0.177 mmol) was used in place of triphenylphosphine. The residue was purified by RBC (6:1→2:1 light petroleum--EtOAc) to afford the aldehyde **25** (21.8 mg, 87%): *R*~f~ 0.21 (2:1 light petroleum--EtOAc); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +11.0 (*c* 1.5, CHCl~3~); ^1^H NMR (CDCl~3~, 500 MHz): *δ* 9.59 (s, 1H, HCO), 7.53--7.31 (m, 5H, Ph), 5.15 (dd, 1H, *J*~2,3~ 10.7, *J*~3,4~ 9.5 Hz, H-3), 4.96 (t, 1H, *J*~4,5~ 9.5 Hz, H-4), 4.84 (d, 1H, *J*~1,2~ 10.7 Hz, H-1), 4.27 (dd, 1H, *J*~5,6a~ 5.3, *J*~6a,6b~ 12.2 Hz, H-6a), 4.17 (dd, 1H, H-6b), 3.76--3.71 (m, 1H, H-5), 2.84 (dd, 1H, *J*~2,7a~ 3.8, *J*~7a,7b~ 16.4 Hz, H-7a), 2.57 (dd, 1H, H-7b), 2.45--2.38 (m, 1H, H-2), 2.10, 2.01, 1.97 (3 × s, 9H, 3 × CH~3~CO); ^13^C NMR (CDCl~3~, 125 MHz): *δ* 198.94 (HCO), 170.69, 170.31, 169.82 (3 × CO), 132.87--128.45 (C-Ph), 86.51 (C-1), 75.67 (C-5), 74.49 (C-3), 69.26 (C-4), 62.47 (C-6), 43.09 (C-7), 40.51 (C-2), 20.81, 20.67, 20.61 (3 × *C*H~3~CO). HRESIMS: Calcd for \[C~20~H~24~O~8~S+Na\]^+^: 447.1084. Found *m/z*: 447.1096.

### 3.2.12. Phenyl 3,4,6-tri-*O*-acetyl-2-*C*-carboxymethyl-2-deoxy-1-thio-α-[d]{.smallcaps}-glucopyranoside (**26**) {#s0095}

Pinnick[@b0105] oxidation of the aldehyde **24** (0.383 g, 0.902 mmol) in the presence of sodium chlorite (1.20 g, 13.04 mmol), sodium dihydrogen phosphate (1.83 g, 15.24 mmol), *tert*-BuOH (26.5 mL, 282 mmol), amylene (7.96 mL, 94.71 mmol) and water (10 mL), essentially as described for compound **21,** furnished a crude residue of **26**. This residue was purified by FCC (1:1:0.02 hexane--Et~2~O--AcOH) to give the white crystalline carboxylic acid **26** (0.369 g, 93%): mp 95--98 °C; *R*~f~ 0.25 (1:1:0.02 hexane--Et~2~O--AcOH); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +195.0 (*c* 1.0, CHCl~3~); ^1^H NMR (CDCl~3~, 500 MHz): *δ* 7.46--7.27 (m, 5H, Ph), 5.77 (d, 1H, *J*~1,2~ 5.1 Hz, H-1), 5.18 (dd, 1H, *J*~2,3~11.7, *J*~3,4~ 9.1 Hz, H-3), 5.03 (dd, 1H, *J*~4,5~ 10.1 Hz, H-4), 4.61--4.56 (m, 1H, H-5), 4.32 (dd, 1H, *J*~5,6a~ 5.1, *J*~6a,6b~ 12.3 Hz, H-6a), 4.05 (dd, 1H, H-6b), 2.90--2.85 (m, 1H, H-2), 2.61 (dd, 1H, *J*~2,7a~ 8.4, *J*~7a,7b~ 17.0 Hz, H-7a), 2.50 (dd, 1H, H-7b), 2.05, 2.04, 2.02 (3 × s, 9H, 3 × CH~3~CO); ^13^C NMR (CDCl~3~, 125 MHz): *δ* 176.64, 170.86, 170.43, 170.03 (4 × CO), 133.10--127.79 (C-Ph), 87.65 (C-1), 71.94 (C-3), 69.75 (C-4), 68.65 (C-5), 62.30 (C-6), 41.70 (C-2), 33.78 (C-7), 20.84, 20.70, 20.61 (3 × *C*H~3~CO). HRESIMS: Calcd for \[C~20~H~24~O~9~S−H\]^−^: 439.1068. Found *m/z*: 439.1085.

### 3.2.13. Phenyl 3,4,6-tri-*O*-acetyl-2-*C*-carboxymethyl-2-deoxy-1-thio-β-[d]{.smallcaps}-glucopyranoside (**27**) {#s0100}

Pinnick[@b0105] oxidation of the aldehyde **25** (20 mg, 0.047 mmol) in the presence of sodium chlorite (63 mg, 0.695 mmol), sodium dihydrogen phosphate (95 mg, 0.794 mmol), *tert*-BuOH (1.40 mL, 14.71 mmol), amylene (413.5 μL, 4.94 mmol) and water (10 mL), essentially as described for compound **21**, gave the crude compound **27**. This material was purified by FCC (1:1:0.02 hexane--Et~2~O--AcOH) and gave the acid **27** as white crystals (19.4 mg, 92%): mp 95--98 °C; *R*~f~ 0.25 (1:1:0.02 hexane--Et~2~O--AcOH); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +10 (*c* 1.0, CHCl~3~); ^1^H NMR (CDCl~3~, 500 MHz): *δ* 7.50--7.31 (m, 5H, Ph), 5.26 (dd, 1H, *J*~2,3~ 10.6 Hz, *J*~3,4~ 9.3, H-3), 4.95 (t, 1H, *J*~4,5~ 9.3 Hz, H-4), 4.92 (d, 1H, *J*~1,2~ 10.9 Hz, H-1), 4.25 (dd, 1H, *J*~5,6a~ 5.3, *J*~6a,6b~ 12.2 Hz, H-6a), 4.17 (dd, 1H, H-6b), 3.75--3.71 (m, 1H, H-5), 2.69 (dd, 1H, *J*~2,7a~ 4.0, *J*~7a,7b~ 17.1 Hz, H-7a), 2.61 (dd, 1H, H-7b), 2.35--2.28 (m, 1H, H-2), 2.09, 2.01, 1.99 (3 × s, 9H, 3 × CH~3~CO); ^13^C NMR (CDCl~3~, 125 MHz): *δ* 176.26, 170.75, 170.49, 169.85 (4 × CO), 132.96--128.37 (C-Ph), 86.24 (C-1), 75.59 (C-5), 73.97 (C-3), 69.43 (C-4), 62.53 (C-6), 41.93 (C-2), 32.94 (C-7), 20.81, 20.70, 20.61 (3 × *C*H~3~CO). HRESIMS: Calcd for \[C~20~H~24~O~9~S−H\]^−^: 439.1068. Found *m/z*: 439.1085.

### 3.2.14. Phenyl 2-*C*-carboxymethyl-2-deoxy-1-thio-α-[d]{.smallcaps}-glucopyranoside (**10**) {#s0105}

To a stirred mixture of the triacetate **26** (75 mg, 0.170 mmol) in acetone (10 mL) at 56 °C was added dropwise a solution of concentrated hydrochloric acid (1 mL) in water (1.8 mL). Stirring was continued overnight at 56 °C, whereafter the mixture was neutralised with TEA, concentrated under reduced pressure and co-evaporated with toluene (2 × 5 mL). The residue was purified by an RPC C18 column (55% MeOH) to furnish the carboxylic acid as white needles **10** (40 mg, 75%): mp 144--146 °C; *R*~f~ 0.38 (55% MeOH); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ +247 (*c* 1.0, MeOH); ^1^H NMR (CD~3~OD, 500 MHz): *δ* 7.49--7.26 (m, 5H, Ph), 5.61 (d, 1H, *J*~1,2~ 4.5 Hz, H-1), 4.12--4.09 (m, 1H, H-5), 3.80 (dd, 1H, *J*~6a,6b~ 12.0 Hz, H-6a), 3.76 (dd, 1H, *J*~5,6b~ 4.9 Hz, H-6b), 3.42--3.34 (m, 2H, H-3, H-4), 2.88 (dd, 1H, *J*~2,7a~ 3.7, *J*~7a,7b~ 16.0 Hz, H-7a), 2.56--2.46 (m, 2H, H-2, H-7b); ^13^C NMR (CD~3~OD, 125 MHz): *δ* 174.48 (COOH), 136.11--128.54, (C-Ph), 90.54 (C-1), 75.13 (C-5), 74.09, 72.93, 62.56 (C-6), 45.29 (C-2), 34.85 (C-7). HRESIMS: Calcd for \[C~14~H~18~O~6~S−H\]^−^: 313.0751. Found *m/z*: 313.0766.

### 3.2.15. Phenyl 2-*C*-carboxymethyl-2-deoxy-1-thio-β-[d]{.smallcaps}-glucopyranoside (**11**) {#s0110}

A methanolic 0.03 M NaOMe (0.43 mL, 0.013 mmol) solution was added to the triacetate **27** (19 mg, 0.043 mmol) in MeOH (1 mL) and the reaction mixture was stirred at room temperature overnight. Afterwards, it was neutralised with Amberlite IR-120 (H^+^) ion-exchange resin, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by an RPC C18 column (55% MeOH) to give the triol as white needles **11** (11 mg, 81%): mp 205--208 °C; *R*~f~ 0.42 (55% MeOH); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ −50.0 (*c* 0.6, MeOH); ^1^H NMR (CD~3~OD, 500 MHz): *δ* 7.54--7.27 (m, 5H, Ph), 4.85 (d, 1H, *J*~1,2~ 10.7 Hz, H-1), 3.86 (dd, 1H, *J*~6a,6b~ 11.9 Hz, H-6a), 3.68 (dd, 1H, *J*~5,6b~ 5.4 Hz, H-6b), 3.51 (t, 1H, *J*~2,3~ = *J*~3,4~ = 8.9 Hz, H-3), 3.34--3.29 (m, 1H, H-5), 3.26 (t, 1H, *J*~4,5~ 8.9 Hz, H-4), 2.73 (dd, 1H, *J*~2,7a~ 3.2, *J*~7a,7b~ 16.6 Hz, H-7a), 2.60 (dd, 1H, H-7b), 2.04--1.96 (m, 1H, H-2); ^13^C NMR (CD~3~OD, 125 MHz): *δ* 174.59 (COOH), 135.78--128.22 (C-Ph), 88.85 (C-1), 81.82 (C-5), 77.85 (C-3), 72.83 (C-4), 63.10 (C-6), 45.59 (C-2), 36.85 (C-7). HRESIMS: Calcd for \[C~14~H~18~O~6~S−H\]^−^: 313.0751. Found *m/z*: 313.0766.

### 3.2.16. Phenyl 2-(*N*-aminocarbonyl)amino-2-deoxy-1-thio-β-[d]{.smallcaps}-glucopyranoside (**12**) {#s0115}

Potassium cyanate (278 mg, 3.42 mmol) was added to a suspension of the known[@b0125] amino-glucopyranoside **28** (607 mg, 2.24 mmol) in water (15 mL). The mixture was stirred in total darkness at room temperature for 4 days. Whereafter, the water was evaporated to dryness under reduced pressure and the residue was co-evaporated with toluene (3 × 20 mL). RPC (25% CH~3~CN) of the residue yielded the ureido compound **12** (458 mg, 65%): mp 220--222 °C (MeOH); *R*~f~ 0.40 (25% CH~3~CN); $\lbrack\alpha\rbrack\,_{\text{D}}^{25}$ −32.0 (*c* 1.5, DMSO); ^1^H NMR (DMSO, 500 MHz): *δ* 7.41--7.17 (m, 5H, Ph), 6.02 (d, 1H, *J* 8.7 Hz, NH), 5.52 (s, 2H, NH~2~), 5.07 (d, 2H, *J* 5.2 Hz, OH-3 and OH-4), 4.81 (d, 1H, *J*~1,2~ 10.3 Hz, H-1), 4.62 (dd, 1H, *J* 5.8, *J* 11.5 Hz, 6-OH), 3.70 (ddd, 1H, *J*~5,6a~ 5.3, *J*~6a,6b~ 11.8 Hz, H-6a), 3.45 (d, 1H, H-6b), 3.40 (ddd, 1H, *J*~2,3~ 9.0 Hz, H-2), 3.30 (dt, 1H, *J*~3,4~ 9.0.Hz, H-3), 3.24--3.21 (m, 1H, H-5), 3.13 (dt, 1H, *J*~4,5~ 9.0 Hz, H-4); ^13^C NMR (DMSO, 125 MHz): *δ* 158.47 (CO), 136.17--125.85 (C-Ph), 86.56 (C-1), 80.87 (C-5), 76.04 (C-3), 70.54 (C-4), 60.97 (C-6), 54.94 (C-2). HRESIMS: Calcd for \[C~13~H~18~N~2~O~5~S+H\]^+^: 315.1009. Found *m/z*: 315.1012.

Supplementary data {#s0125}
==================

Supplementary data 1Spectral data.
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Compound **8** is in the literature, Jackman, J. E. et al. *J. Biol. Chem.***2000**, *275*, 11002--11009, however, no preparative details are given therein.

Supplementary data (additional experimental procedures and partial characterisation data for those intermediates obtained from the sequence **13**→**14**, hydroxamates **16** and **17**, plus the hydroxamic acid **7)** associated with this article can be found, in the online version, at [doi:10.1016/j.carres.2011.02.004](10.1016/j.carres.2011.02.004).
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